Literature DB >> 33422652

Targeting T-type/CaV3.2 channels for chronic pain.

Song Cai1, Kimberly Gomez2, Aubin Moutal2, Rajesh Khanna3.   

Abstract

T-type calcium channels regulate neuronal excitability and are important contributors of pain processing. CaV3.2 channels are the major isoform expressed in nonpeptidergic and peptidergic nociceptive neurons and are emerging as promising targets for pain treatment. Numerous studies have shown that CaV3.2 expression and/or activity are significantly increased in spinal dorsal horn and in dorsal root ganglia neurons in different inflammatory and neuropathic pain models. Pharmacological campaigns to inhibit the functional expression of CaV3.2 for treatment of pain have focused on the development of direct channel blockers, but none have produced lead candidates. Targeting the proteins that regulate the trafficking or transcription, and the ones that modify the channels via post-translational modifications are alternative means to regulate expression and function of CaV3.2 channels and hence to develop new drugs to control pain. Here we synthesize data supporting a role for CaV3.2 in numerous pain modalities and then discuss emerging opportunities for the indirect targeting of CaV3.2 channels.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CaV3.2; Ubiquitination; glycosylation; inflammatory pain; neuropathic pain; phosphorylation

Mesh:

Substances:

Year:  2021        PMID: 33422652      PMCID: PMC8217081          DOI: 10.1016/j.trsl.2021.01.002

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   10.171


  99 in total

1.  Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin.

Authors:  R S Chuang; H Jaffe; L Cribbs; E Perez-Reyes; K J Swartz
Journal:  Nat Neurosci       Date:  1998-12       Impact factor: 24.884

2.  Reducing agents sensitize C-type nociceptors by relieving high-affinity zinc inhibition of T-type calcium channels.

Authors:  Michael T Nelson; Jiwan Woo; Ho-Won Kang; Iuliia Vitko; Paula Q Barrett; Edward Perez-Reyes; Jung-Ha Lee; Hee-Sup Shin; Slobodan M Todorovic
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 3.  What lessons can be learnt from withdrawal of mibefradil from the market?

Authors:  A L Po; W Y Zhang
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

4.  Selective inhibition of CaV3.2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain.

Authors:  Sonja L Joksimovic; Srdjan M Joksimovic; Vesna Tesic; Agustin García-Caballero; Simon Feseha; Gerald W Zamponi; Vesna Jevtovic-Todorovic; Slobodan M Todorovic
Journal:  Sci Signal       Date:  2018-08-28       Impact factor: 8.192

5.  Glycosylation increases potassium channel stability and surface expression in mammalian cells.

Authors:  R Khanna; M P Myers; M Lainé; D M Papazian
Journal:  J Biol Chem       Date:  2001-06-26       Impact factor: 5.157

6.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

7.  Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain.

Authors:  Vinicius M Gadotti; Agustin Garcia Caballero; N Daniel Berger; Clare M Gladding; Lina Chen; Tom A Pfeifer; Gerald W Zamponi
Journal:  Mol Pain       Date:  2015-03-14       Impact factor: 3.395

8.  Upregulation of T-type Ca2+ channels in long-term diabetes determines increased excitability of a specific type of capsaicin-insensitive DRG neurons.

Authors:  Dmytro E Duzhyy; Viacheslav Y Viatchenko-Karpinski; Eugen V Khomula; Nana V Voitenko; Pavel V Belan
Journal:  Mol Pain       Date:  2015-05-20       Impact factor: 3.395

9.  SUMOylation regulates USP5-Cav3.2 calcium channel interactions.

Authors:  Agustin Garcia-Caballero; Fang-Xiong Zhang; Lina Chen; Said M'Dahoma; Junting Huang; Gerald W Zamponi
Journal:  Mol Brain       Date:  2019-08-27       Impact factor: 4.041

10.  Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice.

Authors:  Janelle R Latham; Sriyani Pathirathna; Miljen M Jagodic; Won Joo Choe; Michaela E Levin; Michael T Nelson; Woo Yong Lee; Kathiresan Krishnan; Douglas F Covey; Slobodan M Todorovic; Vesna Jevtovic-Todorovic
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  9 in total

1.  Targeting intrinsically disordered regions facilitates discovery of CaV3.2 inhibitory peptides for AAV-mediated peripheral analgesia.

Authors:  Seung Min Shin; Justas Lauzadis; Brandon Itson-Zoske; Yongsong Cai; Fan Fan; Gayathri Natarajan; Wai-Meng Kwok; Michelino Puopolo; Quinn H Hogan; Hongwei Yu
Journal:  Pain       Date:  2022-04-14       Impact factor: 7.926

2.  CaV3.2 calcium channels: new players in facial pain.

Authors:  Kimberly Gomez; Rajesh Khanna
Journal:  Pain       Date:  2022-04-15       Impact factor: 7.926

Review 3.  Voltage-dependent CaV3.2 and CaV2.2 channels in nociceptive pathways.

Authors:  Lucia Hoppanova; Lubica Lacinova
Journal:  Pflugers Arch       Date:  2022-01-18       Impact factor: 3.657

4.  Secretory carrier-associated membrane protein 2 (SCAMP2) regulates cell surface expression of T-type calcium channels.

Authors:  Leos Cmarko; Robin N Stringer; Bohumila Jurkovicova-Tarabova; Tomas Vacik; Lubica Lacinova; Norbert Weiss
Journal:  Mol Brain       Date:  2022-01-03       Impact factor: 4.041

Review 5.  Central and peripheral contributions of T-type calcium channels in pain.

Authors:  Erika K Harding; Gerald W Zamponi
Journal:  Mol Brain       Date:  2022-05-02       Impact factor: 4.399

Review 6.  Cav3 T-Type Voltage-Gated Ca2+ Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance.

Authors:  Anna Papazoglou; Muhammad Imran Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Jürgen Hescheler; Dan Ehninger; Britta Haenisch; Marco Weiergräber
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 7.  Plant and fungi derived analgesic natural products targeting voltage-gated sodium and calcium channels.

Authors:  Aida Calderon-Rivera; Santiago Loya-Lopez; Kimberly Gomez; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2022-12       Impact factor: 3.493

Review 8.  Normalization of Neuroinflammation: A New Strategy for Treatment of Persistent Pain and Memory/Emotional Deficits in Chronic Pain.

Authors:  Xian-Guo Liu
Journal:  J Inflamm Res       Date:  2022-09-09

Review 9.  T-Type Calcium Channels: A Mixed Blessing.

Authors:  Dario Melgari; Anthony Frosio; Serena Calamaio; Gaia A Marzi; Carlo Pappone; Ilaria Rivolta
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.